NCT02499445

Brief Summary

In patients undergoing off-pump coronary artery bypass (OPCAB) surgery with different anesthesia regimens: remifentanil (0.75 mcg/kg/min) and propofol (TCI effect-site concentration 0.8-1.5 mcg/ml) (Group -RP); remifentanil (0.75 mcg/kg/min) and sevoflurane (end-tidal 0.8 vol%) (Group-RS), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml) (Group-SS), intergroup difference in the level of Troponin I (c-TnI) and creatinine kinase subtype-MB is determined before surgery (control), during vascular graft harvesting (harvesting), after completing graft construction (postgrafting), and one day after surgery (postoperative).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2007

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2014

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 5, 2015

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 16, 2015

Completed
Last Updated

July 16, 2015

Status Verified

July 1, 2015

Enrollment Period

6.9 years

First QC Date

March 5, 2015

Last Update Submit

July 15, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • troponin I

    troponin I for myocardial injury

    one day after surgery

Secondary Outcomes (1)

  • creatinin kinase-MB

    one day after surgery

Study Arms (3)

Remifentanil and propofol

ACTIVE COMPARATOR

remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)

Drug: RemifentanilDrug: propofol

remifentanil and sevoflurane 1

ACTIVE COMPARATOR

remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)

Drug: RemifentanilDrug: sevoflurane 1

sevoflurane 2 and sufentanil

ACTIVE COMPARATOR

sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)

Drug: sevoflurane 2Drug: sufentanil

Interventions

administering remifentanil for anesthesia maintenance

Remifentanil and propofolremifentanil and sevoflurane 1

administering sevoflurane 1 for anesthesia maintenance

remifentanil and sevoflurane 1

administering sevoflurane 2 for anesthesia maintenance

sevoflurane 2 and sufentanil

administering propofol for anesthesia maintenance

Remifentanil and propofol

administering sufentanil for anesthesia maintenance

sevoflurane 2 and sufentanil

Eligibility Criteria

Age19 Years - 72 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient undergoing OPCAB surgery
  • patient signed written informed consent

You may not qualify if:

  • patient with Intra-aortic balloon pump
  • patient with renal replacement therapy
  • patient wants to withdraw the participation to the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Konkuk University Medical Center

Seoul, Seoul, 143-729, South Korea

Location

MeSH Terms

Conditions

Myocardial Ischemia

Interventions

RemifentanilPropofolSufentanil

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsFentanyl

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Anesthesiology

Study Record Dates

First Submitted

March 5, 2015

First Posted

July 16, 2015

Study Start

November 1, 2007

Primary Completion

October 1, 2014

Study Completion

November 1, 2014

Last Updated

July 16, 2015

Record last verified: 2015-07

Locations